Punch & Associates Investment Management Inc. Sells 19,344 Shares of Johnson & Johnson $JNJ

Punch & Associates Investment Management Inc. cut its position in shares of Johnson & Johnson (NYSE:JNJ) by 34.1% in the first quarter, Holdings Channel.com reports. The firm owned 37,380 shares of the company’s stock after selling 19,344 shares during the quarter. Punch & Associates Investment Management Inc.’s holdings in Johnson & Johnson were worth $9,137,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in the company. Vivaldi Capital Management LP boosted its holdings in Johnson & Johnson by 2.4% during the 1st quarter. Vivaldi Capital Management LP now owns 3,243 shares of the company’s stock valued at $793,000 after acquiring an additional 76 shares during the period. Sustainable Insight Capital Management LLC purchased a new stake in Johnson & Johnson in the first quarter worth $232,000. Sentinel Advisory Group LLC purchased a new stake in Johnson & Johnson in the first quarter worth $227,000. Healthcare of Ontario Pension Plan Trust Fund lifted its position in shares of Johnson & Johnson by 29.7% during the first quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,227,947 shares of the company’s stock worth $300,159,000 after purchasing an additional 281,192 shares during the last quarter. Finally, Bollard Group LLC boosted its stake in shares of Johnson & Johnson by 11.6% during the first quarter. Bollard Group LLC now owns 55,723 shares of the company’s stock valued at $13,621,000 after purchasing an additional 5,790 shares during the period. 69.55% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Johnson & Johnson

In related news, EVP Kathryn E. Wengel sold 10,000 shares of the business’s stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $241.15, for a total transaction of $2,411,500.00. Following the transaction, the executive vice president directly owned 114,288 shares in the company, valued at $27,560,551.20. The trade was a 8.05% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.16% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of brokerages have commented on JNJ. HSBC set a $290.00 target price on shares of Johnson & Johnson and gave the stock a “buy” rating in a research note on Monday, July 6th. TD Cowen lifted their price target on shares of Johnson & Johnson from $250.00 to $300.00 and gave the company a “buy” rating in a research note on Monday, July 13th. JPMorgan Chase & Co. increased their price objective on Johnson & Johnson from $250.00 to $260.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 15th. Barclays raised their price objective on Johnson & Johnson from $234.00 to $255.00 and gave the stock an “equal weight” rating in a report on Wednesday, April 15th. Finally, The Goldman Sachs Group reaffirmed a “buy” rating and set a $282.00 target price on shares of Johnson & Johnson in a research report on Thursday, July 16th. One analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $265.30.

Johnson & Johnson Stock Up 1.6%

Shares of Johnson & Johnson stock opened at $263.43 on Friday. The company has a quick ratio of 0.77, a current ratio of 1.03 and a debt-to-equity ratio of 0.46. The company has a market cap of $634.13 billion, a P/E ratio of 30.52, a PEG ratio of 2.50 and a beta of 0.24. The firm’s 50 day moving average price is $242.71 and its 200-day moving average price is $236.32. Johnson & Johnson has a 52-week low of $164.23 and a 52-week high of $269.43.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, July 15th. The company reported $2.90 EPS for the quarter, beating analysts’ consensus estimates of $2.84 by $0.06. The company had revenue of $25.31 billion during the quarter, compared to analysts’ expectations of $25.06 billion. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.86%. Johnson & Johnson’s revenue for the quarter was up 6.6% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.77 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. On average, sell-side analysts predict that Johnson & Johnson will post 11.68 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 8th. Stockholders of record on Tuesday, August 25th will be issued a dividend of $1.34 per share. This represents a $5.36 annualized dividend and a dividend yield of 2.0%. The ex-dividend date is Tuesday, August 25th. Johnson & Johnson’s dividend payout ratio is currently 62.11%.

Johnson & Johnson News Summary

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Analysts highlighted that JNJ raised its outlook, with guidance upgrades adding to investor confidence after the company’s recent earnings beat. Q2 Earnings: Guidance Upgrades Push These 3 Stocks Higher
• Positive Sentiment: JNJ’s Innovative Medicine unit reported strong Q2 growth, helping show resilience even after Stelara patent loss and suggesting momentum can continue into the second half of 2026. J&J’s Innovative Medicine Unit Proves Its Resilience in Q2
• Positive Sentiment: Positive topline Phase 3 data for TECVAYLI and TALVEY showed large reductions in disease progression and death risk in relapsed/refractory multiple myeloma, strengthening JNJ’s oncology pipeline. TECVAYLI® + TALVEY® reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myeloma
• Positive Sentiment: JNJ also received FDA De Novo authorization for its OTTAVA robotic surgical system, expanding its competitiveness in soft-tissue robotic surgery and broadening a potentially important growth platform. Should FDA’s De Novo Nod for OTTAVA Robotic System Require Action From Johnson & Johnson (JNJ) Investors?
• Neutral Sentiment: Several articles framed JNJ as a defensive dividend stock and a steady healthcare holding, which reinforces its safe-haven appeal but is less likely to move the shares on its own. 3 Dividend Stocks Baby Boomers Should Own for the Rest of Their Lives
• Neutral Sentiment: Commentary on JNJ’s steadiness during market volatility and ETF exposure after earnings mainly reflects investor interest in the stock rather than a new fundamental change. ETFs to Buy Post JNJ’s Q2 Earnings Beat & Bullish 2026 Outlook

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.